A capital raise and a regulatory update have investors hitting the sell button. Corium International (NASDAQ: CORI) is down 11% at 11:58 a.m. EST after announcing that it priced $100 million of 5% ...
Corium International, Inc. CORI announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital. Per this agreement, Gurnet will acquire Corium and ...
BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Corium International Inc. (NASDAQ: CORI) shares jumped on ...
First once-weekly transdermal system offering continuous delivery of donepezil, most-commonly prescribed Alzheimer's dementia drug Broadens Corium's CNS drug portfolio BOSTON, Sept. 29, 2022 ...
Corium International Inc (CORI) files its latest 10-K with SEC for the fiscal year ended on September 30, 2017. Corium International Inc is a commercial stage biopharmaceutical company. The Company ...
Corium International (NASDAQ: CORI) is down 11% at 11:58 a.m. EST after announcing that it priced $100 million of 5% convertible senior notes with an initial conversion price equivalent to ...
Corium International, Inc. CORI announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital. Per this agreement, Gurnet will acquire Corium and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results